BWA
ALNY icon

Basecamp Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Basecamp Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Sell
121
-29
-19% -$8.75K 0.01% 630
2026
Q1 		$49.6K Buy
150
+27
+22% +$9.19K 0.01% 553
2025
Q4 		$48.8K Buy
+123
New +$54.4K 0.01% 541

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's ALNY Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 19% in Q2 2026, selling an estimated $8.75K and leaving 121 shares worth $36.4K. The position accounts for 0.01% of the portfolio, ranked #630.

Basecamp Wealth Advisors first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $49.6K in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Basecamp Wealth Advisors held 121 shares of Alnylam Pharmaceuticals worth $36.4K as of Q2 2026.
  • Basecamp Wealth Advisors sold 29 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.75K.
  • Alnylam Pharmaceuticals made up 0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #630 holding.
  • Basecamp Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Alnylam Pharmaceuticals position peaked at $49.6K in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.